WO2005044788A1 - ウレア誘導体およびその製造方法 - Google Patents
ウレア誘導体およびその製造方法 Download PDFInfo
- Publication number
- WO2005044788A1 WO2005044788A1 PCT/JP2004/016526 JP2004016526W WO2005044788A1 WO 2005044788 A1 WO2005044788 A1 WO 2005044788A1 JP 2004016526 W JP2004016526 W JP 2004016526W WO 2005044788 A1 WO2005044788 A1 WO 2005044788A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- compound
- salt
- production method
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
Definitions
- the present invention relates to a urea derivative effective for prevention or treatment of various diseases accompanied by abnormal growth of angiogenesis, and a method for producing the same.
- R 1 represents a hydrogen atom, C alkyl group or C cycloalkyl group
- Patent Document 1 Represents a hydrogen atom or a methoxy group. Is known to exhibit an excellent angiogenesis inhibitory action (Patent Document 1). It is also known that the urea derivative represented by the general formula (C) exhibits a potent, c-kit kinase inhibitory action (Patent Document 2, Non-Patent Document 1).
- Patent Document 1 Although the production method described in Patent Document 1 is useful as a method for producing a urea derivative, there remains room for further improvement in terms of the overall yield and the like. Therefore, there has been a demand for an industrial production method of a urea derivative having a better overall yield and development of an intermediate useful in the production.
- Patent Document 1 discloses an efficient method for producing a perrea compound represented by the general formula (C) and a useful intermediate represented by the general formulas (A-1) and (A-2) according to the present invention. Is not disclosed at all.
- Patent document 1 WO 02/32872 pamphlet
- Patent Document 2 International Publication No. 2004/080462 pamphlet
- An object of the present invention is to provide a novel intermediate for producing a rearea derivative which is effective for prevention or treatment of various diseases accompanied by abnormal proliferation of angiogenesis, and a method for producing the same.
- the present inventors have conducted intensive studies in view of the above circumstances, and as a result, have found a new intermediate for producing a rearea derivative and a method for producing the same, which are effective for the prevention or treatment of various diseases accompanied by abnormal growth of angiogenesis. Heading, the present invention has been completed. That is, the present invention, (1)
- R 1 represents a hydrogen atom, a C alkyl group or a C cycloalkyl group.
- R 1 is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group or a cyclopropyl group, a salt thereof, or a hydrate thereof:
- R 1 is a cyclopropyl group, a salt thereof, or a hydrate thereof:
- Ar is a substituent selected from a halogen atom, a methyl group, a methoxy group and a nitro group Means a C aryl group which may have 1 or 2 (A-
- R 1 is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group or a cyclopropyl group [4].
- Ar is a phenyl group
- R 2 represents a hydrogen atom or a methoxy group
- L represents a leaving group
- R 10 is a hydrogen atom, a methyl group, an ethyl group, an n-propyl group or a cyclopropyl group [10]-[13].
- R 10 is a cyclopropyl group [10]-[13] Production method according to [1]: [16]
- the compound or a salt thereof according to the present invention may be any of an anhydride, a hydrate and a solvate.
- C alkyl group refers to a group having 1 carbon atom.
- a straight-chain or branched-chain alkyl group having 1-16 carbon atoms which is a monovalent group derived by removing one arbitrary hydrogen atom from 16 aliphatic hydrocarbons It means, specifically, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group , Sec—pentyl group, neopentyl Group, 1-methylbutyl group, 2-methylbutyl group, 1,1-dimethylpropyl group, 1,2-dimethylpropyl group, n-hexyl group, isohexyl group, 1-methylpentyl group, 2-methylinopentyl group, 3 —Methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-
- C cycloalkyl group refers to a cyclic C 3-8 alkyl group.
- An aliphatic hydrocarbon group specifically, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, etc., and a cyclopropyl group is preferable. .
- C aryl group refers to an aromatic carbon having 6 to 10 carbon atoms.
- a hydride cyclic group specifically, for example, a phenyl group, an 11-naphthyl group, a 2-naphthyl group and the like, and a phenyl group is preferable.
- Halogen atom used in the present specification means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and is preferably a chlorine atom.
- base refers to an organic base (eg, pyridine, 2,6-lutidine, collidine, triethynoleamine, diisopropylethylamine, diazabicyclo [5.4.0] -7-ene, etc.) or inorganic bases (alkali metal carbonates (eg, cesium carbonate, potassium carbonate, sodium carbonate, etc.), alkali metal alkoxides (eg, potassium t-butoxide, sodium ethoxide, etc.), alkali metals (Eg, potassium hydride, sodium hydride, etc.) and alkali metal hydroxides (eg, potassium hydroxide, sodium hydroxide, etc.).
- organic base eg, pyridine, 2,6-lutidine, collidine, triethynoleamine, diisopropylethylamine, diazabicyclo [5.4.0] -7-ene, etc.
- inorganic bases alkali metal carbonates (eg, cesium carbonate, potassium
- the base used in the step of reacting compound (A-1) with compound (B) to obtain compound (C) is preferably an alkali metal carbonate or an alkali metal alkoxide, more preferably Is cesium carbonate, potassium carbonate or potassium t-butoxide.
- salt used in the present specification, for example, a salt with an inorganic acid, a salt with an organic acid
- Preferred examples of the salt with an inorganic acid include a salt with an inorganic base, a salt with an organic base, and a salt with an acidic or basic amino acid.
- Preferred examples of the salt with an inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid.
- salts with organic acids include, for example, acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfone And salts with an acid, p-toluenesulfonic acid and the like.
- Preferred examples of the salt with an inorganic base include an alkali metal salt such as a sodium salt and a potassium salt, an alkaline earth metal salt such as a calcium salt and a magnesium salt, an aluminum salt, and an ammonium salt.
- Preferred examples of the salt with an organic base include salts with, for example, ethylenamine, diethanolamine, megnolemine, N, N-dibenzylethylenediamine and the like.
- Preferred examples of the salt with an acidic amino acid include, for example, salts with aspartic acid, glutamic acid, and the like.
- Preferred examples of the salt with the basic amino acid include salts with, for example, arginine, lysine, orditin and the like. No.
- the term "leaving group” is not particularly limited as long as it is a group generally known as a leaving group in organic synthesis.
- a halogen atom such as a chlorine atom, a bromine atom and an iodine atom
- an alkylsulfonyloxy group such as a methanesulfonyl / reoxy group, a trifluorosulfonyloxy group and an ethanesulfonyloxy group, for example, a benzenesulfonyloxy group, p —Arylsulfonyloxy groups such as toluenesulfonyloxy group; alkoxy groups such as methoxy group and ethoxy group; and alkylthio groups such as methylthio group and ethylthio group.
- the “leaving group” is preferably a halogen atom such as a chlorine atom, a bromine atom and an iod
- a carbamate-reducing reagent such as phenyl chloroformate
- A-3 such as phenyl chloroformate
- the reaction can also use a base such as pyridine.
- the carbamate reagent (A-3) is used in the amount of 1 to 2 equivalents based on compound (A-4).
- the base is used in the amounts of 1 equivalent to 5 equivalents based on compound (A-4).
- the reaction time is between 10 minutes and 30 hours.
- the reaction temperature is from 0 ° C to the reflux temperature, preferably from 0 ° C to room temperature.
- Compound (A-1) is obtained by reacting the compound (A-2) with an amine derivative R 1 -NH
- reaction solvent dimethylsulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide, tetrahydrofuran, ethyl acetate, acetonitrile, toluene, chloroform and the like can be used.
- the reaction may be carried out by using an organic base (eg, pyridine, triethylenamine, diisopropylethylamine, etc.) or an inorganic base (eg, alkali metal carbonate (eg, cesium carbonate, potassium carbonate, sodium carbonate, etc.), alkali metal hydride (eg, Potassium hydride, sodium hydride, etc.)) can also be used.
- organic base eg, pyridine, triethylenamine, diisopropylethylamine, etc.
- an inorganic base eg, alkali metal carbonate (eg, cesium carbonate, potassium carbonate, sodium carbonate, etc.), alkal
- the amine derivative is used in the amount of 1 to 3 equivalents based on compound (A-2).
- the base is used in the amounts of 1 equivalent to 3 equivalents based on compound (A-2).
- the reaction time is between 10 minutes and 30 hours.
- the reaction temperature is from 0 ° C to the reflux temperature, preferably from 0 ° C to room temperature.
- compound (A-1) is reacted with compound (B) to obtain compound (C).
- compound (C) Use 1-methylpyrrolidone, dimethyl sulfoxide, N, N-dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone, toluene, benzene, etc. as the reaction solvent. be able to.
- an organic base for example, pyridine, 2,6-lutidine, collidine, triethynoleamine, diisopropylethylamine, diazabicyclo [5.4.0] indene force_7-ene, etc.
- an inorganic base alkali
- Metal carbonates eg, cesium carbonate, potassium carbonate, sodium carbonate, etc.
- alkali metal alkoxides eg, potassium t-butoxide, sodium ethoxide, etc.
- alkali metal hydrides eg, potassium hydride, sodium hydride, etc.
- Hydroxides of alkali metals eg, potassium hydroxide, sodium hydroxide, etc.
- the base is preferably an alkali metal carbonate or an alkali metal alkoxide, more preferably cesium carbonate, potassium carbonate or potassium t-butoxide.
- Compound (A-1) is used in the amounts of 1 equivalent to 2 equivalents based on compound (B).
- the base is used in the amount of 1 to 2 equivalents based on compound (B). Reaction times range from 10 minutes to 48 hours.
- the reaction temperature is from room temperature to a reflux temperature, preferably from 40 ° C to 80 ° C.
- purification can be performed by a usual treatment method, for example, by column chromatography using silica gel or an adsorbent resin or by recrystallization from an appropriate solvent.
- Phenylenone N- (2-chloro-1-hydroxyphenyl) carbamate was dissolved in N, N-dimethylformamide (100 mL), and cyclopropylamine (22.7 mL) was added under ice cooling. Stirred overnight at room temperature. Water (400 mL), ethyl acetate (300 mL), and 6N-HC1 (55 mL) were added, and after stirring, the organic layer was separated. The organic layer was washed twice with 10% saline (200 mL), and dried over magnesium sulfate. The prism crystals obtained by concentrating the solvent were washed and filtered with heptane to obtain 22.8 g of the title compound. (77% yield from 4-amino_3_chlorophenol)
- the method for producing a urea derivative according to the present invention makes it possible to efficiently produce a urea derivative effective for prevention or treatment of various diseases accompanied by abnormal growth of angiogenesis by an industrially efficient production method. Further, the intermediate of the urea derivative according to the present invention is useful as an intermediate for efficiently producing the urea derivative.
- the method for producing a urea derivative according to the present invention makes it possible to efficiently produce an urea derivative which is effective for prevention or treatment of various diseases accompanied by abnormal growth of angiogenesis by an industrially efficient production method. Further, the intermediate of the urea derivative according to the present invention is useful as an intermediate for efficiently producing the urea derivative.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005515330A JP4303726B2 (ja) | 2003-11-11 | 2004-11-08 | ウレア誘導体およびその製造方法 |
US10/577,308 US7683172B2 (en) | 2003-11-11 | 2004-11-08 | Urea derivative and process for preparing the same |
EP04818213.3A EP1683785B1 (en) | 2003-11-11 | 2004-11-08 | Urea derivative and process for producing the same |
IL175363A IL175363A (en) | 2003-11-11 | 2006-05-01 | Processes for preparing derivatives of urea |
US12/400,562 US8058474B2 (en) | 2003-11-11 | 2009-03-09 | Urea derivative and process for preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-381249 | 2003-11-11 | ||
JP2003381249 | 2003-11-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/577,308 A-371-Of-International US7683172B2 (en) | 2003-11-11 | 2004-11-08 | Urea derivative and process for preparing the same |
US12/400,562 Division US8058474B2 (en) | 2003-11-11 | 2009-03-09 | Urea derivative and process for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005044788A1 true WO2005044788A1 (ja) | 2005-05-19 |
Family
ID=34567274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016526 WO2005044788A1 (ja) | 2003-11-11 | 2004-11-08 | ウレア誘導体およびその製造方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US7683172B2 (ja) |
EP (1) | EP1683785B1 (ja) |
JP (1) | JP4303726B2 (ja) |
CN (2) | CN100450998C (ja) |
IL (1) | IL175363A (ja) |
WO (1) | WO2005044788A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
US7612208B2 (en) | 2003-12-25 | 2009-11-03 | Eisai R&D Management Co., Ltd. | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
US7973160B2 (en) | 2000-10-20 | 2011-07-05 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
US8058474B2 (en) | 2003-11-11 | 2011-11-15 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2016031841A1 (ja) * | 2014-08-28 | 2016-03-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 高純度キノリン誘導体およびその製造方法 |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
JP7379470B2 (ja) | 2018-09-07 | 2023-11-14 | インデナ エッセ ピ ア | レンバチニブの調製方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
WO2007026864A1 (ja) * | 2005-09-01 | 2007-03-08 | Eisai R & D Management Co., Ltd. | 崩壊性の改善された医薬組成物の製造方法 |
AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
WO2009054004A2 (en) * | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
JP5399926B2 (ja) * | 2008-01-29 | 2014-01-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管阻害物質とタキサンとの併用 |
JP6404242B2 (ja) | 2013-06-26 | 2018-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 |
CN104876864B (zh) * | 2015-06-05 | 2017-03-08 | 北京康立生医药技术开发有限公司 | 一种乐伐替尼的制备方法 |
CN105801481A (zh) * | 2016-05-20 | 2016-07-27 | 湖南欧亚生物有限公司 | 一种乐伐替尼的合成方法 |
WO2017221214A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Crystalline forms of salts of lenvatinib |
WO2017221215A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Salts of lenvatinib |
CN106632033A (zh) * | 2016-10-28 | 2017-05-10 | 北京万全德众医药生物技术有限公司 | 乐伐替尼的一种制备方法 |
CN106854180B (zh) * | 2016-11-30 | 2018-08-31 | 济南轩德化工有限公司 | 一种4-氯-7-甲氧基喹啉-6-酰胺的制备方法 |
CN110590839B (zh) * | 2018-06-13 | 2022-04-05 | 四川海思科制药有限公司 | 一种乐伐替尼衍生物及制备方法和用途 |
CN111484490A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
WO2021217537A1 (zh) * | 2020-04-30 | 2021-11-04 | 天津睿创康泰生物技术有限公司 | 一种乐伐替尼游离碱晶型及其制备方法 |
CN115872906A (zh) * | 2023-01-09 | 2023-03-31 | 山东铂源药业股份有限公司 | 一种乐伐替尼杂质及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
WO2004080966A1 (ja) * | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
WO2004080462A1 (ja) * | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kitキナーゼ阻害剤 |
WO2004101526A1 (ja) * | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキサミドの多形結晶及びその製造方法 |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
ATE85080T1 (de) * | 1984-02-17 | 1993-02-15 | Genentech Inc | Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. |
EP0184365B1 (en) * | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
JPS62168137A (ja) | 1985-12-20 | 1987-07-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料およびその処理方法 |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US4983615A (en) | 1989-06-28 | 1991-01-08 | Hoechst-Roussel Pharmaceuticals Inc. | Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders |
JPH0340486A (ja) | 1989-07-07 | 1991-02-21 | Asahi Chem Ind Co Ltd | 印刷配線基板 |
JP2980326B2 (ja) | 1989-08-31 | 1999-11-22 | 株式会社東芝 | ディスク制御装置 |
US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
GB9105677D0 (en) | 1991-03-19 | 1991-05-01 | Ici Plc | Heterocyclic compounds |
US5367057A (en) * | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
EP0648264A4 (en) * | 1992-06-03 | 1997-10-01 | Univ Case Western Reserve | BANDAGE ALLOWING THE CONTINUOUS APPLICATION OF ORGANIC PRODUCTS. |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
JPH07176103A (ja) | 1993-12-20 | 1995-07-14 | Canon Inc | 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体 |
GB9326136D0 (en) | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
JP3660391B2 (ja) | 1994-05-27 | 2005-06-15 | 株式会社東芝 | 半導体装置の製造方法 |
JPH0848078A (ja) | 1994-08-05 | 1996-02-20 | Nippon Paper Ind Co Ltd | 感熱記録体 |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5656454A (en) * | 1994-10-04 | 1997-08-12 | President And Fellows Of Harvard College | Endothelial cell-specific enhancer |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
JPH08176138A (ja) | 1994-12-19 | 1996-07-09 | Mercian Corp | イソクマリン誘導体 |
US5658374A (en) | 1995-02-28 | 1997-08-19 | Buckman Laboratories International, Inc. | Aqueous lecithin-based release aids and methods of using the same |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
EP2163546B1 (en) | 1995-03-30 | 2016-06-01 | Pfizer Products Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EP0831829B1 (en) | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
US5849759A (en) | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
DE69729583T2 (de) | 1996-04-17 | 2005-06-09 | Bristol-Myers Squibb Pharma Co. | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren |
CA2258093A1 (en) * | 1996-06-28 | 1998-01-08 | Mark E. Duggan | Fibrinogen receptor antagonists |
AU3766897A (en) | 1996-07-13 | 1998-02-09 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
US6207669B1 (en) | 1996-07-13 | 2001-03-27 | Glaxo Wellcome Inc. | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
AU733551B2 (en) | 1996-09-25 | 2001-05-17 | Astrazeneca Ab | Qinoline derivatives inhibiting the effect of growth factors such as VEGF |
WO1998014437A1 (fr) | 1996-09-30 | 1998-04-09 | Nihon Nohyaku Co., Ltd. | Derives de 1,2,3-thiadiazole et sels de ces derives, agents en usage dans l'agriculture et l'horticulture pour lutter contre les maladies vegetales, et procede d'utilisation correspondant |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
EP0946554A1 (en) | 1996-11-27 | 1999-10-06 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
CA2275777A1 (en) | 1997-01-29 | 1998-07-30 | Louise Richman Levine | Treatment for premenstrual dysphoric disorder |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
EP0968206B8 (en) | 1997-02-19 | 2007-01-24 | Berlex, Inc. | N-heterocyclic derivatives as nos inhibitors |
US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
ES2151467T3 (es) | 1997-05-23 | 2005-03-01 | Bayer Corporation | Arilureas para el tratamiento de enfermedades inflamatorias o inmunomoduladoras. |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
WO1999001738A2 (en) * | 1997-06-30 | 1999-01-14 | University Of Maryland, Baltimore | Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis |
JP3765918B2 (ja) | 1997-11-10 | 2006-04-12 | パイオニア株式会社 | 発光ディスプレイ及びその駆動方法 |
JP4194678B2 (ja) | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
PT1043995E (pt) | 1997-12-22 | 2007-01-31 | Bayer Pharmaceuticals Corp | Inibição da actividade de p38-quinase utilização de ureias heterocíclicas substituídas com arilo ou heteroarilo |
WO1999032111A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
CZ299156B6 (cs) | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití |
NZ505843A (en) | 1997-12-22 | 2003-06-30 | Bayer Ag | Diphenyl ureas compounds for treating cancer and raf kinase related diseases |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
PL347717A1 (en) | 1998-11-19 | 2002-04-22 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
HU230789B1 (en) | 1999-01-22 | 2018-05-02 | Kyowa Hakko Kirin Co | Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
ES2351699T3 (es) * | 1999-02-10 | 2011-02-09 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de la angiogénesis e intermedios de los mismos. |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
JP2000328080A (ja) | 1999-03-12 | 2000-11-28 | Shin Etsu Chem Co Ltd | シートベルト用低摩擦化処理剤 |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
US6524583B1 (en) * | 1999-04-28 | 2003-02-25 | Board Of Regents, The University Of Texas System | Antibody methods for selectively inhibiting VEGF |
AU4778500A (en) | 1999-05-20 | 2000-12-12 | Takeda Chemical Industries Ltd. | Composition containing ascorbic acid salt |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
WO2001012600A1 (en) | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
CO5200835A1 (es) | 1999-09-28 | 2002-09-27 | Bayer Corp | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
JP2001131071A (ja) | 1999-10-29 | 2001-05-15 | Meiji Seika Kaisha Ltd | 非晶質および非晶質を含有する医薬組成物 |
WO2001032926A2 (en) | 1999-11-01 | 2001-05-10 | Curagen Corporation | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
MXPA02004594A (es) | 1999-11-16 | 2002-10-23 | Boehringer Ingelheim Pharma | Derivados de urea como agentes anti-inflamatorios. |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
AU784266B2 (en) | 1999-12-22 | 2006-03-02 | Sugen, Inc. | Indolinone derivatives for modulation of c-kit tyrosine kinase |
WO2001047931A1 (fr) | 1999-12-24 | 2001-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Derives de purine fondue |
US7135466B2 (en) * | 1999-12-24 | 2006-11-14 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives and drugs containing the same |
EP1255752B1 (en) | 2000-02-15 | 2007-08-08 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
CA2411278A1 (en) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
ES2290199T3 (es) * | 2000-11-22 | 2008-02-16 | Novartis Ag | Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce. |
WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
US6960580B2 (en) | 2001-03-08 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | Nitrogenous heterocyclic substituted quinoline compounds |
HUP0304093A3 (en) | 2001-04-06 | 2008-08-28 | Wyeth Corp | Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them |
EP1382604B1 (en) * | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Quinoline derivative having azolyl group and quinazoline derivative |
BR0209647A (pt) | 2001-05-16 | 2004-07-27 | Novartis Ag | Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico |
CN100415720C (zh) | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物 |
GB0117144D0 (en) | 2001-07-13 | 2001-09-05 | Glaxo Group Ltd | Process |
GB0119467D0 (en) * | 2001-08-09 | 2001-10-03 | Smithkline Beecham Plc | Novel compound |
EP1451348B1 (en) * | 2001-09-10 | 2015-08-12 | Meso Scale Technologies, LLC | Methods, reagents, kits and apparatus for protein function analysis |
US20040266779A1 (en) | 2001-09-27 | 2004-12-30 | Anderson Kenneth C. | Use of c-kit inhibitors for the treatment of myeloma |
US6765012B2 (en) | 2001-09-27 | 2004-07-20 | Allergan, Inc. | 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
EP1435959A2 (en) * | 2001-10-09 | 2004-07-14 | University of Cincinnati | Inhibitors of the egf receptor for the treatment of thyroid cancer |
EP1447405A4 (en) | 2001-10-17 | 2005-01-12 | Kirin Brewery | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS |
TW200300348A (en) | 2001-11-27 | 2003-06-01 | American Cyanamid Co | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
AU2003211594A1 (en) * | 2002-03-05 | 2003-09-16 | Eisai Co., Ltd. | Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor |
JP2005520834A (ja) | 2002-03-20 | 2005-07-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 小細胞肺癌の同定、診断、および治療のための方法および組成物 |
EP1535910A4 (en) | 2002-05-01 | 2007-03-14 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORILATION OF THE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
AU2003251968A1 (en) | 2002-07-16 | 2004-02-02 | Children's Medical Center Corporation | A method for the modulation of angiogenesis |
US7169936B2 (en) * | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
JP4183193B2 (ja) | 2002-08-30 | 2008-11-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素芳香環誘導体 |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
CA2499682A1 (en) | 2002-10-09 | 2004-04-22 | Kosan Biosciences, Inc. | Epo d + 5-fu/gemcitabine |
EP2596792A1 (en) | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
JP4749660B2 (ja) | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME |
WO2004039785A1 (en) | 2002-11-01 | 2004-05-13 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
JP2006508184A (ja) | 2002-11-06 | 2006-03-09 | サイクラセル・リミテッド | Cdk阻害剤及びゲムシタビンを含む医薬組成物 |
GB0226434D0 (en) | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
AR042042A1 (es) | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
NZ540878A (en) | 2003-01-14 | 2008-06-30 | Cytokinetics Inc | Compounds, compositions and methods |
EP1603864A4 (en) * | 2003-03-05 | 2007-04-11 | Celgene Corp | DIPHENYLETHYLENE COMPOUNDS AND THEIR USE |
CN1761682A (zh) * | 2003-03-14 | 2006-04-19 | 大正制药株式会社 | 单克隆抗体与产生该单克隆抗体的杂交瘤 |
WO2005016323A2 (en) * | 2003-08-15 | 2005-02-24 | Ab Science | Use of c-kit inhibitors for treating type ii diabetes |
MXPA06002018A (es) * | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | Bencimidazolilo n-sustituidos inhibidores de c-kit. |
AU2004273615B2 (en) | 2003-09-23 | 2009-01-15 | Novartis Ag | Combination of a VEGF receptor inhibitor with a chemotherapeutic agent |
EP2609919A3 (en) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
RU2402567C2 (ru) | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
CN101337931B (zh) | 2003-12-25 | 2010-09-29 | 卫材R&D管理有限公司 | 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法 |
KR100799535B1 (ko) * | 2004-02-27 | 2008-01-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규 피리딘 유도체 및 피리미딘 유도체(2) |
KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
NZ551406A (en) * | 2004-06-03 | 2010-03-26 | Hoffmann La Roche | Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor) |
WO2006030947A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
US8772269B2 (en) * | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US20060079494A1 (en) * | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
CA2586420A1 (en) | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
CA2589274A1 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
DE602006021401D1 (de) | 2005-02-28 | 2011-06-01 | Eisai R&D Man Co Ltd | Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs |
EP1859797A4 (en) | 2005-02-28 | 2011-04-13 | Eisai R&D Man Co Ltd | NEW SIMULTANEOUS USE OF A SULPHONAMIDE COMPOUND AND A MEDIUM AGAINST CANCER |
CN101233111A (zh) | 2005-06-23 | 2008-07-30 | 卫材R&D管理有限公司 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法 |
US7550483B2 (en) * | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
JP5066446B2 (ja) | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
AU2006309551B2 (en) * | 2005-11-07 | 2012-04-19 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
-
2004
- 2004-11-08 JP JP2005515330A patent/JP4303726B2/ja not_active Expired - Fee Related
- 2004-11-08 CN CNB2004800330716A patent/CN100450998C/zh active Active
- 2004-11-08 EP EP04818213.3A patent/EP1683785B1/en active Active
- 2004-11-08 US US10/577,308 patent/US7683172B2/en not_active Expired - Fee Related
- 2004-11-08 WO PCT/JP2004/016526 patent/WO2005044788A1/ja active Application Filing
- 2004-11-08 CN CN200810128200XA patent/CN101337930B/zh active Active
-
2006
- 2006-05-01 IL IL175363A patent/IL175363A/en active IP Right Grant
-
2009
- 2009-03-09 US US12/400,562 patent/US8058474B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032872A1 (en) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Nitrogenous aromatic ring compounds |
WO2004080462A1 (ja) * | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kitキナーゼ阻害剤 |
WO2004080966A1 (ja) * | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
WO2004101526A1 (ja) * | 2003-04-22 | 2004-11-25 | Eisai Co., Ltd. | 4-(3-クロロ-4-(シクロプロピルアミノカルボニル)アミノフェノキシ)-7-メトキシ-6-キノリンカルボキサミドの多形結晶及びその製造方法 |
Non-Patent Citations (2)
Title |
---|
GARNER G. ET AL.: "In vitro activity of sorghum-selective fluorophenyl urea herbicides", PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY, vol. 24, no. 3, 1985, pages 285 - 297, XP002986961 * |
NUGIEL D.A. ET AL.: "Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2 Probing the indeno ring substituent pattern", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 24, 2002, pages 5224 - 5232, XP002986962 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7973160B2 (en) | 2000-10-20 | 2011-07-05 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US8372981B2 (en) | 2000-10-20 | 2013-02-12 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic derivatives |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
US8058474B2 (en) | 2003-11-11 | 2011-11-15 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
US7612208B2 (en) | 2003-12-25 | 2009-11-03 | Eisai R&D Management Co., Ltd. | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
US9504746B2 (en) | 2004-09-17 | 2016-11-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US7550483B2 (en) | 2005-06-23 | 2009-06-23 | Eisai R&D Management Co., Ltd. | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same |
US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
EP3524595B1 (en) | 2014-08-28 | 2022-08-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
EP3524595A1 (en) * | 2014-08-28 | 2019-08-14 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10407393B2 (en) | 2014-08-28 | 2019-09-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US10822307B2 (en) | 2014-08-28 | 2020-11-03 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
JPWO2016031841A1 (ja) * | 2014-08-28 | 2017-06-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 高純度キノリン誘導体およびその製造方法 |
EP4089076A1 (en) * | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
WO2016031841A1 (ja) * | 2014-08-28 | 2016-03-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 高純度キノリン誘導体およびその製造方法 |
US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
JP7379470B2 (ja) | 2018-09-07 | 2023-11-14 | インデナ エッセ ピ ア | レンバチニブの調製方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101337930B (zh) | 2010-09-08 |
US8058474B2 (en) | 2011-11-15 |
CN1878751A (zh) | 2006-12-13 |
CN100450998C (zh) | 2009-01-14 |
CN101337930A (zh) | 2009-01-07 |
EP1683785B1 (en) | 2013-10-16 |
IL175363A (en) | 2013-10-31 |
US20090171112A1 (en) | 2009-07-02 |
IL175363A0 (en) | 2006-09-05 |
US20070037849A1 (en) | 2007-02-15 |
EP1683785A1 (en) | 2006-07-26 |
US7683172B2 (en) | 2010-03-23 |
JPWO2005044788A1 (ja) | 2007-11-29 |
EP1683785A4 (en) | 2007-08-29 |
JP4303726B2 (ja) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005044788A1 (ja) | ウレア誘導体およびその製造方法 | |
JP5817079B2 (ja) | 6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミド、またはそれの薬学的に許容される塩を調製するための方法 | |
CA2611927C (en) | Process for the preparation of dihydroquinazolines | |
EP2346850A1 (en) | A method for the preparation of dabigatran and its intermediates | |
JP5805880B2 (ja) | 1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)−プロパ−2−エン−1−オン塩酸塩の製造方法および該方法で用いられる中間体 | |
AU2008304956A1 (en) | Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same | |
JP2009007273A (ja) | ジアミノピリミジン化合物の製造方法 | |
IL182439A (en) | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the intermediates and aripiprazole | |
JP7379470B2 (ja) | レンバチニブの調製方法 | |
WO2006132424A1 (ja) | 4(3h)-キナゾリノン誘導体の製造方法 | |
WO2012102393A1 (ja) | ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体 | |
JP4553338B2 (ja) | アミノアクリル酸誘導体およびその製造方法 | |
JP2020503338A (ja) | 6−アミノイソキノリンを調製する方法 | |
JP4356111B2 (ja) | N−(2−アミノ−1,2−ジシアノビニル)ホルムアミジンの製造方法 | |
RU2315747C2 (ru) | Способ получения ацетиленового соединения | |
JP4807675B2 (ja) | 高純度ピペラジン誘導体塩酸塩の製造方法 | |
JP4425366B2 (ja) | N−ベンジル−3−ヒドロキシアゼチジンの製造法 | |
KR20230032513A (ko) | 카모스타트 메실산염의 제조방법 | |
KR100242857B1 (ko) | 비시클릭 아민의 제조 방법 | |
EP1698611A1 (en) | Process for producing phenylacetic acid derivative | |
KR101095706B1 (ko) | 몬테루카스트산 또는 그 나트륨염의 신규한 제조 방법 | |
JPH0446175A (ja) | 5―ヒドロキシ―3,4―メチレンジオキシ安息香酸誘導体の製造法 | |
JP2022025121A (ja) | プロリンアミド化合物の製造方法 | |
JPH069619A (ja) | キノロンカルボン酸誘導体の製造方法 | |
JP2016500093A (ja) | 4−(シクロプロピルメトキシ)−n−(3,5−ジクロロ−1−オキシド−4−ピリジル)−5−メトキシピリジン−2−カルボキサミドを製造する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480033071.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515330 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007037849 Country of ref document: US Ref document number: 10577308 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 175363 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004818213 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2045/CHENP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004818213 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10577308 Country of ref document: US |